Table of Contents
ISRN Endocrinology
Volume 2012, Article ID 504756, 13 pages
Review Article

Role of Gut-Related Peptides and Other Hormones in the Amelioration of Type 2 Diabetes after Roux-en-Y Gastric Bypass Surgery

1Division of Endocrinology, Department of Internal Medicine, American University of Beirut-Medical Center, P.O. Box 11-0236/D23 Riad El-Solh, Beirut 1107 2020, Lebanon
2Department of Surgery, American University of Beirut-Medical Center, P.O. Box 11-0236/D23, Riad El-Solh, Beirut 1107 2020, Lebanon

Received 10 January 2012; Accepted 6 February 2012

Academic Editors: J. E. Gunton, D. Iafusco, and N. Tentolouris

Copyright © 2012 Mirella P. Hage et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Bariatric surgery is currently the most effective and durable therapy for obesity. Roux-en-Y gastric bypass surgery, the most commonly performed procedure worldwide, causes substantial weight loss and improvement in several comorbidities associated with obesity, especially type 2 diabetes. Several mechanisms are proposed to explain the improvement in glucose metabolism after RYGB surgery: the caloric restriction and weight loss per se, the improvement in insulin resistance and beta cell function, and finally the alterations in the various gastrointestinal hormones and adipokines that have been shown to play an important role in glucose homeostasis. However, the timing, exact changes of these hormones, and the relative importance of these changes in the metabolic improvement postbariatric surgery remain to be further clarified. This paper reviews the various changes post-RYGB in adipokines and gut peptides in subjects with T2D.